Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.64 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.42 |
| ▸ | HPGDS | O60760 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | CD74 | P04233 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | COMT | P21964 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29998937 | 0.79 | IDO1 (1.00) | IDO1PIM1NOTUMHPGDSCDK1 | |
| SCHEMBL1501845 | 0.79 | IDO1 (1.00) | IDO1PIM1NOTUMHPGDSCDK1 | |
| SCHEMBL5536764 | 0.77 | IDO1 (0.50) | IDO1PIM1NOTUMHPGDSCDK1 | |
| SCHEMBL27917554 | 0.77 | IDO1 (0.96) | IDO1PIM1NOTUMHPGDSCDK1 | |
| SCHEMBL4551394 | 0.72 | ALDH1A1 (0.47) | CDK2ALDH1A1POLB | |
| SCHEMBL23923926 | 0.71 | IDO1 (0.64) | IDO1PIM1NOTUMHPGDSCDK1 | |
| SCHEMBL30837200 | 0.71 | IDO1 (0.64) | IDO1PIM1NOTUMHPGDSCDK2 | |
| SCHEMBL5527507 | 0.69 | IDO1 (0.34) | IDO1 | |
| SCHEMBL15094515 | 0.68 | ALDH1A1 (0.56) | ALDH1A1 | |
| SCHEMBL2098518 | 0.67 | ERN1 (0.41) | CDK2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710038-B2 | Pyrazole kinase modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | MAP3K1, MAP3K3, MAP3K5 | IDO1 1615/4885PIM1 323/4885NOTUM 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.